Dr. Jeong is one of the renowned research gurus in the biology of Transcription Factors, especially in oncology applications, with deep insight into the chemistry of the protein and its interaction with DNA. During the last 20+ years, he has been working to dive deep into the Transcription Factor's behavior and determined the way to make transcription factor proteins behave properly in the cancer and tumor microenvironment. During a period of research at the National Cancer Center, he was involved in myriad areas of translational research spanning from basic experiments to clinical studies, collaborating with pharmaceutical companies and developing anticancer drug candidates or consulting with them by validating their new target molecules utilizing his platform. He has a proven track record of setting and executing value-building project strategies, particularly strategic patent portfolios.

Most recently, he led a research support group at National OncoVenture, National Cancer Center, working with both the drug development and clinical translational divisions, on the main projects of Chongundang, Hanmi, KRIBB, CrystalGenomics, Oscotec Inc., etc.
Dr. Jeong received his Ph.D. from Seoul National University.

Dr. Yang is an accomplished cancer researcher with extensive experience in academia as well as the pharmaceutical industry. She is recognized for her expertise in cancer biology and molecular therapeutics, particularly regarding insights into targeted drug therapy, tumor microenvironments, epigenetics, microbiomes, and nanoparticle-based drug delivery therapy.

Throughout her career, she has been engaging in translational studies as an innovator possessing the ability to integrate emerging technologies with newly discovered cancer science. Her major R&D contributions were as the head of the Biomedical Research Center at AT Dental Hospital and her period working at Yonsei University and Ewha Women’s University as an associate and research professor. She started her career as a postdoc fellow at KIRAMS and a project manager for new drug development in the industry field.
Dr. Yang earned her Ph.D. in biochemistry at the Korea University.

Kyung-Ohk is an accomplished pharmaceutical researcher and scientist with more than 17 years of experience in small-molecule drug discovery and development. She is one of the few experts in this area of transcription factor field and has been working with Dr. Jeong, leading the R&D of transcription factors in cancer biology.
Most recently, she led an R&D team of Transcription Factor at the National cancer center, with the considerable contribution to build the TF screening platform of PDIM-M, which was expanded to apply various kinds of target transcription factors that involve cancer progress.

Previously, she took part in the Catholic University of Korea R&D as a researcher. During her MSc. course, she established the principle of drug efficacy testing and had proven the scientific rationale supporting the drug development process for TF target, which is now the basis for current TF research programs. She has contributed articles to numerous publications in the field of cancer research and is an inventor or co-inventor on several published or pending patents.
Kyung-Ohk has a Master of Science in Molecular Biomedicine at the Catholic University of Korea.

Dr.Lee is an accomplished pharmaceutical researcher and scientist with over 14 years of experience in both small-molecule and biologics drug discovery and development.
Most recently, he served as Sr. Director of new drug development for stroke and oncology indications at Myungmoon Bio Inc. and Mirare BioPharm Inc., where he led several R&D teams, spanning from research to clinical development of four investigational drug candidates.

Dr. Lee also has experience in a wide range of fields. He covered the natural extract sector at the Korea Institute of Oriental Medicine (KIOM), cardiovascular R&D at Chungnam National University as a research professor and quality management ofGMP at KCI Ltd.
Dr. Lee earned his Ph.D. in Life Science and Pharmacy at Chungbuk National University.

Yongnam Jang is in charge of patent strategies of Incurix pipelines. He has experienced and worked in various pharmaceutical related fields such as not only intellectual property right but also R&D planning, development planning, licensing in/out, overseas sales and so forth in Daewoong pharmaceutical company, Korea United pharm inc. and an affiliate of CHA medical group, etc.

In particular, as an expert in the field of intellectual property right for about 25 years, he was involved in securing the patent right for Korea's first bio new drug, and has various patent litigation experience with global pharmaceutical companies. Based on his diverse pharmaceutical experience including intellectual property right, he is expected to contribute to building strategic patent portfolios in the full cycle development stage of Incurix new drugs.
He holds a master’s degree in law from Yonsei University.